

Bart Williams Named to Daily Journal's 2025 'Leading Commercial Litigators' List

February 5, 2025

LOS ANGELES, February 5, 2025 - Proskauer, a leading international law firm, is pleased to share that partner <u>Bart Williams</u> has been named as one of the *Daily Journal's* 2025 Leading Commercial Litigators. This annual list recognizes prominent commercial litigators who handle some of the most consequential cases in California and nationally.

Bart is one of the nation's most sought-after trial lawyers with extensive experience across commercial litigation, white collar criminal defense and internal corporate investigations. Known for his legal acumen, strategic approach and persuasive advocacy, Bart is frequently called upon just months or even weeks before a trial to deliver a win. A longtime member of the American College of Trial Lawyers, Bart boasts an impressive track record of victories in both jury and bench trials nationwide. His legal prowess has established him as a trusted trial counsel and "go-to" lawyer for numerous Fortune 500 companies in high-stakes, headline-making matters in recent years.

Most recently, he was lead trial counsel for Netflix, director/writer Ava DuVernay, and writer Attica Locke in a defamation case in federal court in New York brought by Linda Fairstein, former head of the Manhattan DA's sex crimes unit. The matter related to the defendants' series "When They See Us," which recounts the wrongful convictions of the Central Park 5. The plaintiff alleged that the series' portrayal of her by actress Felicity Huffman depicted her in a false and defamatory light. Bart's leadership led to an extremely successful resolution for the clients when the plaintiff decided to settle the case on the eve of trial with no payment to her or her lawyers, and no confidentiality provision related to the settlement.

Bart previously secured a full defense victory for Gilead in a \$3.6 billion antitrust case on allegations that the pharmaceutical company struck an anticompetitive "pay-for-delay" patent settlement related to two of its HIV medications following a six-week trial. The verdict is only the third ever in reverse payment cases of this type, and the first ever to find for the defense on grounds of both the absence of a payment and the absence of market power for the brand in the relevant market.

Bart has also been recognized by the *Los Angeles Business Journal* and the *Los Angeles Times* on the 2025 "Leaders of Influence: Minority Attorneys" list and 2024 Business of Law magazine, respectively.

Read Bart's profile: <u>Leading Commercial Litigators 2025</u>

About Proskauer

The world's leading organizations and global players choose Proskauer to represent them when they need it the most. With 800+ lawyers in key financial centers around the world, we are known for our pragmatic and commercial approach. Proskauer is the place to turn when a matter is complex, innovative and game-changing. We work seamlessly across practices, industries and jurisdictions with asset managers, private equity and venture capital firms, Fortune 500 and FTSE companies, major sports leagues, entertainment industry legends and other industry-redefining companies.

Proskauer has a full-service litigation practice with extensive trial experience in virtually every major forum across the globe. We take a collaborative approach to representing defendants and plaintiffs, multinationals, middle-market and small-cap businesses, financial institutions, partnerships and individuals, with one thing in mind – driving successful outcomes for our clients.

Recent successful representations include a landmark victory for Sanderson Farms in a \$7 billion broiler chicken antitrust conspiracy case; a decisive victory for Gilead Sciences, Inc. in a \$3.6 billion antitrust case; a victory for Shamrock Capital Advisors in a high-profile \$1 billion lawsuit brought by the founders and other minority shareholders of FanDuel; and representing Monsanto in a case brought by multiple plaintiffs who claimed Roundup caused their non-Hodgkin's lymphoma.

• Bart H. Williams

Partner